Bulk Price 80036-89-1 Global Manufacturer 2026
- Market Pricing: Gram-scale catalog prices range from $25 to $75, while industrial bulk orders negotiate significantly lower rates per kilogram.
- Purity Standards: Pharmaceutical grade material typically requires >99% purity with strict control over sulfonate impurities.
- Supply Chain: Verified global manufacturers offer capacity up to 50 metric tons annually with full COA and MSDS documentation.
In the pharmaceutical synthesis landscape, the demand for high-quality building blocks remains constant. Methyl 4-amino-5-(ethylsulfonyl)-2-methoxybenzoate, identified by CAS 80036-89-1, serves as a critical precursor in the production of substituted benzamides. As we approach 2026, procurement managers and process chemists must navigate fluctuating raw material costs and varying purity standards. This compound, often recognized as a key Amisulpride intermediate, requires precise manufacturing controls to ensure the ethylsulfonyl group remains intact during esterification and amination steps.
Understanding the commercial viability of this chemical requires a deep dive into production scalability. The molecular formula C11H15NO5S and a molecular weight of 273.31 g/mol dictate specific handling requirements. Industrial buyers must look beyond simple catalog listings and evaluate the synthesis route employed by the supplier. Efficient routes minimize side products, such as over-sulfonated derivatives, which can comp downstream purification and impact the final bulk price.
Volume-Based Pricing Tiers for 80036-89-1
Market analysis indicates a sharp divergence between research-scale and production-scale pricing. Small packaging, such as 50mg to 25g units, often commands premium pricing due to packaging and quality control overheads. Data suggests catalog prices for these small quantities can range from $25 to $75 per unit. However, this metric is misleading for industrial procurement.
When transitioning to kilogram or metric ton scales, the cost structure shifts dramatically. Verified suppliers often list baseline bulk indicators around $10.00 per KG, though final contracts depend on purity specifications and delivery terms. For large-scale operations requiring 100 tons or more, pricing becomes highly negotiable. The key driver here is the industrial purity level. Material specified at 99.0% min is standard for generic synthesis, but pharmaceutical-grade batches requiring specific impurity profiles (e.g., limiting Amisulpride Impurity 5) will incur higher processing costs.
Buyers should also consider the HS Code 2922500090 for customs planning, as tariffs can influence the landed cost. A reliable global manufacturer will provide transparent breakdowns of FOB costs versus CIF terms, ensuring no hidden fees disrupt the supply chain budget.
Comparing Bulk Costs vs Gram-Scale Catalog Prices
The disparity between gram-scale and bulk costs is rooted in process efficiency. Small-scale production often utilizes laboratory-grade reagents and batch processing, which is labor-intensive. In contrast, bulk manufacturing leverages continuous flow chemistry or large-scale batch reactors to optimize reaction yields. For Methyl 4-amino-5-(ethylsulfonyl)-2-methoxybenzoate, the sulfonation step is critical. Efficient heat management during this exothermic reaction prevents degradation, thereby improving overall yield and reducing the cost per unit.
Furthermore, storage and stability play a role in pricing. This compound is a solid that should be kept in a dark place under an inert atmosphere at room temperature. Suppliers who invest in proper warehousing to maintain stability without degradation can offer better long-term value. Catalog prices often include a premium for immediate availability and small-pack logistics, whereas bulk contracts allow for scheduled production runs that align with the buyer's consumption rate.
Procurement teams should request samples for HPLC analysis before committing to large orders. Verifying the absence of unknown peaks and confirming the boiling point (predicted at 514.5±50.0 °C) ensures the material meets technical specifications. This due diligence prevents costly downstream failures during the final drug substance synthesis.
Requesting Quotes from Verified Global Manufacturers
Securing a competitive quote requires engaging with suppliers who possess robust quality assurance systems. When evaluating potential partners, request a Certificate of Analysis (COA) that details not just the main assay, but also specific impurities. Given the safety profile, which includes GHS07 warning symbols and hazard statements H315, H319, and H335, proper handling documentation is non-negotiable.
NINGBO INNO PHARMCHEM CO.,LTD. stands as a premier global manufacturer offering these technical advantages and bulk supply capabilities. With a focus on consistent quality and scalable production, they provide a reliable source for Methyl 4-amino-5-(ethylsulfonyl)-2-methoxybenzoate. Partnering with an established entity ensures access to technical support regarding the synthesis route and regulatory compliance.
When sourcing high-purity Amisulpride intermediate, buyers should prioritize suppliers who can demonstrate a supply ability of at least 50 metric tons per year. This capacity indicates the infrastructure needed to handle large orders without delaying production timelines. Additionally, verify that the supplier can provide MSDS files and adhere to international safety standards for irritants.
Technical Specifications Overview
To assist in vendor qualification, the following table outlines the critical physical and chemical properties expected from a high-quality batch.
| Property | Specification |
|---|---|
| CAS Number | 80036-89-1 |
| Chemical Name | Methyl 4-amino-5-(ethylsulfonyl)-2-methoxybenzoate |
| Molecular Formula | C11H15NO5S |
| Molecular Weight | 273.31 g/mol |
| Purity Standard | >99.0% (HPLC) |
| Appearance | White Solid |
| Storage Conditions | Dark place, Inert atmosphere, Room temperature |
| Hazard Class | Irritant (GHS07) |
In conclusion, securing the best bulk price for 80036-89-1 in 2026 involves looking beyond initial catalog figures. It requires a partnership with a manufacturer capable of delivering consistent industrial purity at scale. By focusing on verified supply chains and technical compliance, pharmaceutical companies can ensure stable production of their final therapeutic agents.